Aptevo Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Aptevo Therapeutics Inc. on June 2, 2023. The filing details the voting outcomes for three proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Three proposals were voted upon at the Annual Meeting:
- Proposal 1: Election of Directors
- Zsolt Harsanyi, Ph.D.: Elected with 967,133 votes FOR, 343,098 WITHHELD, and 2,566,806 BROKER NON-VOTES.
- Barbara Lopez Kunz: Elected with 716,175 votes FOR, 594,056 WITHHELD, and 2,566,806 BROKER NON-VOTES.
- Proposal 2: Ratification of Independent Auditor
- Moss Adams LLP was ratified as the independent registered public accounting firm for 2023.
- Votes: 3,581,428 FOR, 276,500 AGAINST, 19,109 ABSTAIN.
- Proposal 3: Executive Compensation (Say-on-Pay)
- The non-binding advisory proposal regarding named executive officer compensation was approved.
- Votes: 969,344 FOR, 332,792 AGAINST, 8,095 ABSTAIN, 2,566,806 BROKER NON-VOTES.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Both director nominees were successfully elected to serve until the 2026 Annual Meeting.
- Broker non-votes were significant (2,566,806) for the director election and executive compensation proposals, indicating a large portion of shares held by brokers did not receive voting instructions.
- The ratification of Moss Adams LLP received strong support with over 3.5 million votes in favor.
- Investors should refer to the definitive proxy statement filed on April 18, 2023, for detailed background on the proposals and executive compensation specifics.